4 models fit United Therapeutics Corporation Common Stock and they partly agree: 2 of 4 land within 15% of the average.
Two or more of our models back this value.
Premium(i)Silver71
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
ACCE opinionUnited Therapeutics Corporation Common Stock (UTHR)
Fair value (4 models)
$514
ACCE price target
$510
Rating
Overvalued
Horizon
12 months
Fair value published on 21 Oct 2026, 12:04 CEST; previously $604 since 12 Oct 2026, 00:00 CEST.
ACCE price target published on 25 Sept 2026, 00:00 CEST.
Price used: $588 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, EV/EBITDA comparison, and Graham number.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
14.4% above
-12.6% to fair value
ACCE score
68
out of 100
Analysts
73% buy
15 covering
P/E
20.9x
forward 16.4x
1-year return
+37.8%
Dividend yield
0.00%
United Therapeutics Corporation Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
United Therapeutics makes Orenitram (oral treprostinil) and Remodulin for pulmonary arterial hypertension, plus Tyvaso inhaled treprostinil, and it has a dominant, high-barrier franchise in a small, specialist patient population. The 86.1% gross margin and 42.2% operating margin reflect how little the business spends to produce each dose and how entrenched prescribers are. Revenue is currently shrinking, down 1.9%, so the thesis rests on whether the Tyvaso franchise and the pipeline can return the top line to growth. The stock trades at 19.7x trailing and 18.1x forward earnings with a 19.3% ROE, a reasonable multiple for a business this profitable if the growth question resolves. At a 23.6B market cap, it merits a deeper look focused on the revenue trajectory and the timing of pipeline readouts.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
high
Revenue decline amid valuation premium
Revenue fell 1.9% YoY while P/S of 7.5x and forward P/E of 18.1x remain elevated. Earnings growth (+13.4%) driven by margin expansion, not top-line strength.
moderate
Insider selling concentration
Last 10 disclosures show $25.39M in sales, zero buys. Insider ownership at +2.0% suggests limited conviction at current price levels.
moderate
ACCE Growth score weak relative to valuation
Growth component scores only 27/100 despite 18% 5-year CAGR. Current price $549.16 sits above model fair value midpoint of $510, leaving limited margin of safety.
AI research notes
AI-assisted·How I use AIWritten Oct 11, 2026 · figures from 2026-10-11 · prices to Oct 23, 2026
Why it could do well
Net margin of 41.6% and ROE of 19.3% show the core business generates exceptional returns on capital deployed.
Consensus values the stock 10.0% above current price, with 73% of analysts rating Buy or Strong Buy.
Forward P/E of 18.1x trades below the 23.8x sector median despite a 5-year revenue growth rate of 18.0% annually.
Why it could disappoint
Revenue contracted 1.9% year over year, signaling the core franchise faces near-term headwinds.
Free cash flow yield of 2.4% is thin relative to the 5.2% risk-free rate, leaving little margin for error.
The stock is priced for only 7.1% annual cash flow growth over five years, leaving limited upside if execution falters.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 4, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where UTHR's valuation models land
Price
$587.50
Model fair value
$514
Model range
$325 to $648
Fair value $514
Price $588
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
Dividend discount
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores